| 应用 |
A TLR7 activator and angiogenesis inhibitor. |
| 产品介绍 |
|
| 生化机理 |
Imiquimod is a derivative of imidazoquinolinamine that inhibits angiogenesis and is an immune response modifier. Studies have reported that Imiquimod has the ability to downregulate metastasis and induce alpha-interferon (IFN-α). Additionally, Imiquimod is a TLR7 (toll-like receptor 7) agonist which induces plasmacytoid dendritic cell (pDC) maturation. Imiquimod acts on dendritic cells expressing TLR7, and induces an immune response. Nuclear factor-B helps mediate the activity of Imiquimod, and is involved in increasing chemokine and cytokine levels. The antiangiogenic property of Imiquimod has been shown to be mediated by IL-18. Research shows that Imiquimod can induce apoptosis in cancer cells. Also suggested to be an activator of caspase-3 and NFκB. |
| 别名 |
咪喹莫特; 1-异丁基-1H-咪唑[4.5-C]喹啉-4-胺基;1-(2-甲基丙基)-4-氨基-1H-咪唑并[4,5-c]喹啉;Aldara; R 837; Zyclara;1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine;4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline;1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine |
